Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01776840




Registration number
NCT01776840
Ethics application status
Date submitted
24/01/2013
Date registered
28/01/2013
Date last updated
28/08/2024

Titles & IDs
Public title
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Scientific title
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma
Secondary ID [1] 0 0
PCI-32765MCL3002
Secondary ID [2] 0 0
CR100967
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Mantle Cell Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Bendamustine
Treatment: Drugs - Rituximab
Treatment: Drugs - Ibrutinib
Treatment: Drugs - Placebo

Placebo comparator: Treatment Arm A -

Experimental: Treatment Arm B -


Treatment: Drugs: Bendamustine
90 mg/m2 administered intravenously on Days 1-2, Cycles 1-6

Treatment: Drugs: Rituximab
375 mg/m2 administered intravenously on Day 1, Cycles 1-6; if complete response or partial response is achieved, 375 mg/m2 is administered on Day 1 of every second cycle for a maximum of 12 additional doses

Treatment: Drugs: Ibrutinib
560 mg (4 x 140 mg capsules) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end

Treatment: Drugs: Placebo
4 capsules administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or the final analysis of progression-free survival
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival (PFS)
Timepoint [1] 0 0
Up to 97 months
Secondary outcome [1] 0 0
Overall Survival
Timepoint [1] 0 0
Up to 97 months
Secondary outcome [2] 0 0
Complete Response Rate
Timepoint [2] 0 0
Up to 97 months
Secondary outcome [3] 0 0
Time-to-Next Treatment
Timepoint [3] 0 0
Up to 97 months
Secondary outcome [4] 0 0
Percentage of Participants With Overall Response
Timepoint [4] 0 0
Up to 97 months
Secondary outcome [5] 0 0
Minimal Residual Disease (MRD)-Negative Response Rate
Timepoint [5] 0 0
Up to 97 months
Secondary outcome [6] 0 0
Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Questionnaire
Timepoint [6] 0 0
Up to 97 months
Secondary outcome [7] 0 0
Duration of Response (DoR)
Timepoint [7] 0 0
Up to 97 months
Secondary outcome [8] 0 0
Duration of Complete Response (DoCR)
Timepoint [8] 0 0
Up to 97 months
Secondary outcome [9] 0 0
Time to Response
Timepoint [9] 0 0
Up to 97 months
Secondary outcome [10] 0 0
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Timepoint [10] 0 0
Up to 97 months
Secondary outcome [11] 0 0
Oral Plasma Clearance (CL/F) of Ibrutinib
Timepoint [11] 0 0
Day 2 of Cycles 1, 2 and 3 (each cycle was of 28 days)
Secondary outcome [12] 0 0
Oral Volume of Distribution at Steady State of Ibrutinib
Timepoint [12] 0 0
Day 2 of Cycles 1, 2 and 3 (each cycle was of 28 days)
Secondary outcome [13] 0 0
Area Under the Concentration Curve of Ibrutinib During 24 Hours After Dosing at Steady State
Timepoint [13] 0 0
Day 2 of Cycles 1, 2 and 3 (each cycle was of 28 days)
Secondary outcome [14] 0 0
Minimum Observed Plasma Concentration of Ibrutinib
Timepoint [14] 0 0
Day 2 of Cycles 1, 2 and 3 (each cycle was of 28 days)
Secondary outcome [15] 0 0
Maximum Observed Plasma Concentration of Ibrutinib
Timepoint [15] 0 0
Day 2 of Cycles 1, 2 and 3 (each cycle was of 28 days)

Eligibility
Key inclusion criteria
* Diagnosis of mantle cell lymphoma (MCL) reviewed and approved by central laboratory: diagnosis must include morphology and expression of either cyclin D1 in association with other relevant markers (eg, CD19, CD20, PAX5 and CD5) or evidence of t(11;14) as assessed by cytogenetics, fluorescent in situ hybridization (FISH), or polymerase chain reaction (PCR)
* Clinical Stage II, III, or IV by Ann Arbor Classification
* At least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma
* No prior therapies for MCL
* Eastern Cooperative Oncology Group (ECOG) performance status grade 0 or 1
* Hematology and biochemical laboratory values within protocol-defined limits
* Agrees to protocol-defined use of effective contraception
* Negative blood or urine pregnancy test at screening
Minimum age
65 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Major surgery within 4 weeks of random assignment
* Known central nervous system lymphoma
* Diagnosed or treated for malignancy other than MCL, except: malignancy treated with curative intent and with no known active disease present for >=3 years before random assignment; adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; adequately treated cervical carcinoma in situ without evidence of disease
* Patients for whom the goal of therapy is tumor debulking prior to stem cell transplant
* History of stroke or intracranial hemorrhage within 6 months prior to random assignment
* Requires anticoagulation with warfarin or equivalent vitamin K antagonists
* Requires treatment with strong CYP3A inhibitors
* Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification
* Vaccinated with live, attenuated vaccines within 4 weeks of random assignment
* Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous antibiotics
* Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
16/05/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
24/06/2024
Sample size
Target
Accrual to date
Final
523
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Adelaide
Recruitment hospital [2] 0 0
- Auchenflower
Recruitment hospital [3] 0 0
- Box Hill
Recruitment hospital [4] 0 0
- Concord
Recruitment hospital [5] 0 0
- Douglas
Recruitment hospital [6] 0 0
- Gosford
Recruitment hospital [7] 0 0
- Hobart
Recruitment hospital [8] 0 0
- Prahran
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Auchenflower
Recruitment postcode(s) [3] 0 0
- Box Hill
Recruitment postcode(s) [4] 0 0
- Concord
Recruitment postcode(s) [5] 0 0
- Douglas
Recruitment postcode(s) [6] 0 0
- Gosford
Recruitment postcode(s) [7] 0 0
- Hobart
Recruitment postcode(s) [8] 0 0
- Prahran
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Iowa
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New Mexico
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
North Dakota
Country [19] 0 0
United States of America
State/province [19] 0 0
Oregon
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
South Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
South Dakota
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Vermont
Country [26] 0 0
United States of America
State/province [26] 0 0
Washington
Country [27] 0 0
Argentina
State/province [27] 0 0
Buenos Aires
Country [28] 0 0
Argentina
State/province [28] 0 0
Ciudad Autonoma de Buenos Aires
Country [29] 0 0
Argentina
State/province [29] 0 0
Cordoba
Country [30] 0 0
Argentina
State/province [30] 0 0
La Capital
Country [31] 0 0
Argentina
State/province [31] 0 0
Parana
Country [32] 0 0
Belgium
State/province [32] 0 0
Antwerpen
Country [33] 0 0
Belgium
State/province [33] 0 0
Brugge
Country [34] 0 0
Belgium
State/province [34] 0 0
Brussels
Country [35] 0 0
Belgium
State/province [35] 0 0
Gent
Country [36] 0 0
Belgium
State/province [36] 0 0
Leuven
Country [37] 0 0
Belgium
State/province [37] 0 0
Wilrijk
Country [38] 0 0
Belgium
State/province [38] 0 0
Yvoir
Country [39] 0 0
Brazil
State/province [39] 0 0
Barretos
Country [40] 0 0
Brazil
State/province [40] 0 0
Goiania
Country [41] 0 0
Brazil
State/province [41] 0 0
Porto Alegre
Country [42] 0 0
Brazil
State/province [42] 0 0
Ribeirao Preto
Country [43] 0 0
Brazil
State/province [43] 0 0
Rio de Janeiro
Country [44] 0 0
Brazil
State/province [44] 0 0
Sao Paulo
Country [45] 0 0
Brazil
State/province [45] 0 0
São Paulo
Country [46] 0 0
Canada
State/province [46] 0 0
Alberta
Country [47] 0 0
Canada
State/province [47] 0 0
British Columbia
Country [48] 0 0
Canada
State/province [48] 0 0
Ontario
Country [49] 0 0
Canada
State/province [49] 0 0
Quebec
Country [50] 0 0
China
State/province [50] 0 0
Beijing
Country [51] 0 0
China
State/province [51] 0 0
Chengdu
Country [52] 0 0
China
State/province [52] 0 0
Guangzhou
Country [53] 0 0
China
State/province [53] 0 0
Hangzhou
Country [54] 0 0
China
State/province [54] 0 0
Shanghai
Country [55] 0 0
China
State/province [55] 0 0
Tianjin
Country [56] 0 0
Czechia
State/province [56] 0 0
Brno
Country [57] 0 0
Czechia
State/province [57] 0 0
Hradec Kralove
Country [58] 0 0
Czechia
State/province [58] 0 0
Praha 10
Country [59] 0 0
France
State/province [59] 0 0
Creteil
Country [60] 0 0
France
State/province [60] 0 0
F-75 730 Paris Cedex 15
Country [61] 0 0
France
State/province [61] 0 0
Grenoble
Country [62] 0 0
France
State/province [62] 0 0
Nantes
Country [63] 0 0
France
State/province [63] 0 0
Paris
Country [64] 0 0
France
State/province [64] 0 0
Pessac
Country [65] 0 0
France
State/province [65] 0 0
Tours Cedex 9
Country [66] 0 0
Germany
State/province [66] 0 0
Berlin
Country [67] 0 0
Germany
State/province [67] 0 0
Heidelberg
Country [68] 0 0
Germany
State/province [68] 0 0
Jena
Country [69] 0 0
Germany
State/province [69] 0 0
Mainz
Country [70] 0 0
Germany
State/province [70] 0 0
München
Country [71] 0 0
Germany
State/province [71] 0 0
TÿBINGEN
Country [72] 0 0
Germany
State/province [72] 0 0
Ulm
Country [73] 0 0
Germany
State/province [73] 0 0
Villingen-Schwenningen
Country [74] 0 0
Greece
State/province [74] 0 0
Athens Attica
Country [75] 0 0
Greece
State/province [75] 0 0
Athens
Country [76] 0 0
Greece
State/province [76] 0 0
Thessalonikis
Country [77] 0 0
Hungary
State/province [77] 0 0
Budapest N/a
Country [78] 0 0
Hungary
State/province [78] 0 0
Debrecen
Country [79] 0 0
Hungary
State/province [79] 0 0
Kaposvár
Country [80] 0 0
Hungary
State/province [80] 0 0
Pecs
Country [81] 0 0
Hungary
State/province [81] 0 0
Szeged
Country [82] 0 0
Ireland
State/province [82] 0 0
Dublin
Country [83] 0 0
Ireland
State/province [83] 0 0
Galway
Country [84] 0 0
Israel
State/province [84] 0 0
Afula
Country [85] 0 0
Israel
State/province [85] 0 0
Beer-Sheva
Country [86] 0 0
Israel
State/province [86] 0 0
Haifa
Country [87] 0 0
Israel
State/province [87] 0 0
Jerusalem
Country [88] 0 0
Israel
State/province [88] 0 0
Nahariya
Country [89] 0 0
Israel
State/province [89] 0 0
Petach Tikva
Country [90] 0 0
Israel
State/province [90] 0 0
Ramat-Gan
Country [91] 0 0
Israel
State/province [91] 0 0
Tel Aviv
Country [92] 0 0
Israel
State/province [92] 0 0
Zerifin
Country [93] 0 0
Japan
State/province [93] 0 0
Fukuoka
Country [94] 0 0
Japan
State/province [94] 0 0
Hiroshima
Country [95] 0 0
Japan
State/province [95] 0 0
Kyoto
Country [96] 0 0
Japan
State/province [96] 0 0
Nagoya
Country [97] 0 0
Japan
State/province [97] 0 0
Osaka
Country [98] 0 0
Japan
State/province [98] 0 0
Sapporo
Country [99] 0 0
Japan
State/province [99] 0 0
Sendai-shi
Country [100] 0 0
Japan
State/province [100] 0 0
Suita
Country [101] 0 0
Japan
State/province [101] 0 0
Tokyo
Country [102] 0 0
Korea, Republic of
State/province [102] 0 0
Gyeonggi-do
Country [103] 0 0
Korea, Republic of
State/province [103] 0 0
Jeollanam-do
Country [104] 0 0
Korea, Republic of
State/province [104] 0 0
Seoul
Country [105] 0 0
Mexico
State/province [105] 0 0
Monterrey
Country [106] 0 0
Mexico
State/province [106] 0 0
Oaxaca
Country [107] 0 0
Netherlands
State/province [107] 0 0
Amsterdam Zuidoost
Country [108] 0 0
Netherlands
State/province [108] 0 0
Dordrecht
Country [109] 0 0
Netherlands
State/province [109] 0 0
Groningen
Country [110] 0 0
Netherlands
State/province [110] 0 0
Leiden
Country [111] 0 0
Netherlands
State/province [111] 0 0
Rotterdam
Country [112] 0 0
Netherlands
State/province [112] 0 0
Utrecht
Country [113] 0 0
Poland
State/province [113] 0 0
Bydgoszcz
Country [114] 0 0
Poland
State/province [114] 0 0
Krakow
Country [115] 0 0
Poland
State/province [115] 0 0
Olsztyn
Country [116] 0 0
Poland
State/province [116] 0 0
Warszawa
Country [117] 0 0
Poland
State/province [117] 0 0
Wroclaw
Country [118] 0 0
Puerto Rico
State/province [118] 0 0
San Juan
Country [119] 0 0
Russian Federation
State/province [119] 0 0
Chelyabinsk
Country [120] 0 0
Russian Federation
State/province [120] 0 0
Ekaterinburg
Country [121] 0 0
Russian Federation
State/province [121] 0 0
Krasnodar
Country [122] 0 0
Russian Federation
State/province [122] 0 0
Moscow N/a
Country [123] 0 0
Russian Federation
State/province [123] 0 0
Moscow
Country [124] 0 0
Russian Federation
State/province [124] 0 0
Nizhny Novgorod
Country [125] 0 0
Russian Federation
State/province [125] 0 0
Novosibirsk
Country [126] 0 0
Russian Federation
State/province [126] 0 0
Petrozavodsk
Country [127] 0 0
Russian Federation
State/province [127] 0 0
Rostov-Na-Donu
Country [128] 0 0
Russian Federation
State/province [128] 0 0
Ryazan
Country [129] 0 0
Russian Federation
State/province [129] 0 0
Sochi
Country [130] 0 0
Russian Federation
State/province [130] 0 0
St-Petersburg
Country [131] 0 0
Russian Federation
State/province [131] 0 0
St.Petersurg
Country [132] 0 0
Russian Federation
State/province [132] 0 0
Syktyvkar
Country [133] 0 0
Russian Federation
State/province [133] 0 0
Volgograd
Country [134] 0 0
Slovakia
State/province [134] 0 0
Banska Bystrica
Country [135] 0 0
Slovakia
State/province [135] 0 0
Bratislava
Country [136] 0 0
Slovakia
State/province [136] 0 0
Kosice
Country [137] 0 0
Slovakia
State/province [137] 0 0
Martin
Country [138] 0 0
Slovakia
State/province [138] 0 0
Presov 1
Country [139] 0 0
Spain
State/province [139] 0 0
Barcelona
Country [140] 0 0
Spain
State/province [140] 0 0
Madrid
Country [141] 0 0
Spain
State/province [141] 0 0
Oviedo
Country [142] 0 0
Spain
State/province [142] 0 0
Palma De Mallorca
Country [143] 0 0
Spain
State/province [143] 0 0
Salamanca
Country [144] 0 0
Spain
State/province [144] 0 0
Santiago De Compostela
Country [145] 0 0
Sweden
State/province [145] 0 0
Linköping
Country [146] 0 0
Sweden
State/province [146] 0 0
Lund
Country [147] 0 0
Sweden
State/province [147] 0 0
Stockholm
Country [148] 0 0
Sweden
State/province [148] 0 0
Umeaa
Country [149] 0 0
Sweden
State/province [149] 0 0
Uppsala
Country [150] 0 0
Taiwan
State/province [150] 0 0
Changhua
Country [151] 0 0
Taiwan
State/province [151] 0 0
Kaohsiung County
Country [152] 0 0
Taiwan
State/province [152] 0 0
Taichung
Country [153] 0 0
Taiwan
State/province [153] 0 0
Tainan
Country [154] 0 0
Taiwan
State/province [154] 0 0
Taipei
Country [155] 0 0
Taiwan
State/province [155] 0 0
Taoyuan
Country [156] 0 0
Turkey
State/province [156] 0 0
Adana
Country [157] 0 0
Turkey
State/province [157] 0 0
Ankara
Country [158] 0 0
Turkey
State/province [158] 0 0
Diyarbakir
Country [159] 0 0
Turkey
State/province [159] 0 0
Istanbul
Country [160] 0 0
Turkey
State/province [160] 0 0
Izmir
Country [161] 0 0
Turkey
State/province [161] 0 0
Kayseri
Country [162] 0 0
Turkey
State/province [162] 0 0
Mersin
Country [163] 0 0
Ukraine
State/province [163] 0 0
Cherkassy
Country [164] 0 0
Ukraine
State/province [164] 0 0
Donetsk
Country [165] 0 0
Ukraine
State/province [165] 0 0
Khmelnitskiy
Country [166] 0 0
Ukraine
State/province [166] 0 0
Kiev
Country [167] 0 0
Ukraine
State/province [167] 0 0
Lviv
Country [168] 0 0
United Kingdom
State/province [168] 0 0
Canterbury
Country [169] 0 0
United Kingdom
State/province [169] 0 0
Glasgow
Country [170] 0 0
United Kingdom
State/province [170] 0 0
Leeds
Country [171] 0 0
United Kingdom
State/province [171] 0 0
Leicester
Country [172] 0 0
United Kingdom
State/province [172] 0 0
Liverpool
Country [173] 0 0
United Kingdom
State/province [173] 0 0
London
Country [174] 0 0
United Kingdom
State/province [174] 0 0
Manchester
Country [175] 0 0
United Kingdom
State/province [175] 0 0
Plymouth
Country [176] 0 0
United Kingdom
State/province [176] 0 0
Southampton
Country [177] 0 0
United Kingdom
State/province [177] 0 0
Sutton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Pharmacyclics LLC.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the efficacy and safety of ibrutinib given in combination with bendamustine and rituximab in patients 65 years of age or older with newly diagnosed mantle cell lymphoma.
Trial website
https://clinicaltrials.gov/study/NCT01776840
Trial related presentations / publications
Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernandez-Rivas JA, Hong X, Kim SJ, Lewis D, Mishima Y, Ozcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M; SHINE Investigators. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3.
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01776840